VKTX vs. VTRS, MRNA, RDY, PCVX, SRPT, QGEN, ASND, ROIV, RVMD, and LEGN
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.
Viking Therapeutics vs.
Viatris (NASDAQ:VTRS) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
Viatris has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.
Viatris has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
79.9% of Viatris shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 0.1% of Viatris shares are owned by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Viking Therapeutics had 10 more articles in the media than Viatris. MarketBeat recorded 12 mentions for Viking Therapeutics and 2 mentions for Viatris. Viking Therapeutics' average media sentiment score of 0.54 beat Viatris' score of -0.20 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Viatris presently has a consensus price target of $13.67, suggesting a potential upside of 21.48%. Viking Therapeutics has a consensus price target of $97.29, suggesting a potential upside of 185.55%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Viatris.
Viking Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Viking Therapeutics' return on equity.
Viking Therapeutics received 605 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 79.97% of users gave Viking Therapeutics an outperform vote while only 35.48% of users gave Viatris an outperform vote.
Summary
Viking Therapeutics beats Viatris on 10 of the 18 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VKTX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free VKTX Stock Alerts